Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
45.40
-0.30 (-0.66%)
Jul 30, 2026, 1:05 PM CST

Medigen Vaccine Biologics Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-289.01-281.71-80.47-1,160-1,4751,410
Depreciation & Amortization
143.9140.46134.99130127.26112.33
Other Amortization
1.321.331.451.170.630.22
Loss (Gain) From Sale of Assets
10.289.2-0.41---
Loss (Gain) From Sale of Investments
-1.35--1.429.6416.550.07
Stock-Based Compensation
39.4931.0114.1618.3175.6168.82
Other Operating Activities
36.13-3.3471.32-16.6619.32-0.02
Change in Accounts Receivable
7.56-11.9931.0845.29445.79-635.73
Change in Inventory
10.9458.31-68.43161.1518.71-486.06
Change in Accounts Payable
4.37-2.79-12.5-82.6421.7265.63
Change in Unearned Revenue
-----111.41111.41
Change in Other Net Operating Assets
3.5610.45-49.03411.02-353.41-67.03
Operating Cash Flow
-32.81-49.0940.75-482.56-1,214579.89
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-143.81-50.64-34.3-38.69-139.17-133.63
Sale of Property, Plant & Equipment
3.293.290.87--120
Sale (Purchase) of Intangibles
-1.14-1.14-0.68-2.27-1.17-1.34
Investment in Securities
-206.46201,050636.38-2,279-881.8
Other Investing Activities
-231.7-6.811.2974.4134.74-33.93
Investing Cash Flow
-579.83-35.31,018669.83-2,285-930.69

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-----30
Long-Term Debt Issued
----1,755-
Total Debt Issued
787.1---1,75530
Short-Term Debt Repaid
------30
Long-Term Debt Repaid
--39.19-1,740-11.78-11.56-1.93
Total Debt Repaid
-41.27-39.19-1,740-11.78-11.56-31.93
Net Debt Issued (Repaid)
745.83-39.19-1,740-11.781,744-1.93
Issuance of Common Stock
--3.4713.371,57955.68
Other Financing Activities
------2.58
Financing Cash Flow
745.83-39.19-1,7361.593,32351.18

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
--0.1100.35-0.11
Net Cash Flow
133.19-123.58-677.51188.87-175.44-299.73

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-176.62-99.726.46-521.25-1,353446.26
Free Cash Flow Growth
------
Free Cash Flow Margin
-29.26%-16.26%1.07%-133.78%-370.64%13.60%
Free Cash Flow Per Share
-0.54-0.300.02-1.59-4.181.39
Levered Free Cash Flow
-111.27-3.72-81.08-164.31-744.24-288.35
Unlevered Free Cash Flow
-105.181.79-69.27-140.83-727.43-284.59

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
9.218.667.727.327.536.02
Change in Working Capital
26.4353.98-98.88534.8221.39-1,012